HELQ and osteosarcoma: Liu et al. demonstrated that HELQ confers an anti-invasion phenotype to osteosarcoma (OS) cells by activating the CHK1 signaling pathway, suggesting that HELQ is a promising therapeutic target for OS cells and other malignancies [67].